Opendata, web and dolomites


COmmercializing first-in-class dCTPase Inhibitors for treatment of hematological Cancers

Total Cost €


EC-Contrib. €






 CODIC project word cloud

Explore the words cloud of the CODIC project. It provides you a very rough idea of what is the project "CODIC" about.

attract       medical    nucleoside    medicinal    company    revealed    market    networks    science    combination    prepare    owns    treatment    replication    rnai    nm    house    10    cells    clinical    explore    agency    cancer    purified    secure    ab    vitro    ip    induces    effort    degradation    gt    commercial    perform    tool    potent    oxcia    synergistically    plan    cell    cytidine    pharmacokinetic    enzymatic    clinicians    protein    inhibitor    analogues    nontransformed    inhibitors    hits    exclusive    agencies    throughput    discuss    screening    translational    compounds    assay    patients    death    erc    ic50    direction    plays    genetic    profit    impd    viability    rights    validate    anti    shows    preclinical    therapy    bodies    model    commercialization    therapies    screen    regulatory    repair    th1217    license    dividing    65    strategy    inhibit    grant    dna    chemistry    business    start    vivo    foundation    dctpase    sirna    mu    holds    drug    trials    toxicity    apoptosis    investments    selective   

Project "CODIC" data sheet

The following table provides information about the project.


Organization address
address: Nobels Vag 5
postcode: 17177

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-01-01   to  2017-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 94˙738.00
2    OXCIA AB SE (SOLNA) participant 55˙262.00


 Project objective

In our ERC grant GEnetic NEtworks as a tool for anti-CAncer Drug Development we used siRNA screening and genetic networks to identify dCTPase being involved in DNA repair and replication. Further studies revealed that dCTPase plays a role in the degradation of nucleoside analogues used in cancer treatment. We then used an RNAi approach to validate dCTPase as a target to improve nucleoside analogue therapy. The dCTPase protein was purified and we set up an enzymatic high-throughput assay to screen >65,000 compounds, which generated hits that inhibit dCTPase (IC50~1-10μM). Using in house medicinal chemistry we developed TH1217, a low nM potent and selective dCTPase inhibitor with favourable pharmacokinetic properties. TH1217 synergistically induces apoptosis and cell death in combination with cytidine analogue treatment in cancer cells in vitro and in vivo, but shows no increased toxicity in nontransformed dividing cells. Here, we want to explore the commercial potential of the dCTPase inhibitors identified in the ERC grant. In this programme, we will, with the company Oxcia AB, establish the viability of the business programme using technical analysis, develop a business strategy and direction, specifically secure IP, perform market analysis, develop a business plan, manage preclinical development and prepare for clinical trials in collaboration with clinicians and regulatory bodies, IMPD application to Medical Products Agency and identify and discuss with potential commercialization partners and funding agencies to support cost of clinical trials. We have a non-profit foundation that owns our IP rights in an effort to secure long term support for translational science aimed at bringing new therapies to patients. In our planned business model, we start a new company that holds an exclusive license to the IP from the foundation which is used to develop the overall business programme and attract investments.


year authors and title journal last update
List of publications.
2016 Sabin Llona-Minguez, Andreas Höglund, Sylvain A. Jacques, Lars Johansson, José Manuel Calderón-Montaño, Magnus Claesson, Olga Loseva, Nicholas C. K. Valerie, Thomas Lundbäck, Javier Piedrafita, Giovanni Maga, Emmanuele Crespan, Laurent Meijer, Estefanía Burgos Morón, Pawel Baranczewski, Ann-Louise Hagbjörk, Richard Svensson, Elisee Wiita, Ingrid Almlöf, Torkild Visnes, Fredrik Jeppsson, Kristmundur Sigmundsson, Annika Jenmalm Jensen, Per Artursson, Ann-Sofie Jemth, Pål Stenmark, Ulrika Warpman Berglund, Martin Scobie, Thomas Helleday
Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1
published pages: 1140-1148, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01741
Journal of Medicinal Chemistry 59/3 2019-07-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CODIC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CODIC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  


The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More